Literature DB >> 20236952

Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis.

Tünde Minier1, Zoltán Nagy, Zsófia Bálint, Helka Farkas, Judit Radics, Gábor Kumánovics, Tamás Czömpöly, Diána Simon, Cecília Varjú, Péter Németh, László Czirják.   

Abstract

OBJECTIVES: To evaluate the construct validity of the European Scleroderma Study Group (EScSG) activity index and to propose modifications if necessary.
METHODS: One hundred and thirty-one consecutive patients were investigated and re-evaluated 1 year later. Modified Rodnan skin score (MRSS), skin ulcers and joint contracture numbers, hand anatomic index (HAI), BMI, spirometry, carbon monoxide diffusing capacity (DL(CO)), left ventricular ejection fraction, pulmonary arterial hypertension, HAQ Disability Index (HAQ-DI), patient skin self-assessment questionnaire and several biomarkers were recorded, in addition to the data required for the EScSG activity index. Statistical analysis was performed by categorical principal component analysis (CATPCA).
RESULTS: The EScSG activity index appeared in the same dimension as the HAQ-DI, ulcer score and joint contractures, MRSS, patient-reported skin score and HAI by CATPCA. Parameters of lung involvement appeared in another dimension. We constructed a 12-point activity index that was equally associated with both dimensions, by adding the forced vital capacity/DL(CO), change in DL(CO), change in the ulcer scores, HAQ-DI and patient-reported skin score. Biomarkers including vascular endothelial growth factor, soluble P-selectin glycoprotein ligand-1, CRP and albumin were related to both the EScSG and the 12-point index, though they did not improve the total variance of the model.
CONCLUSION: The construct validity of the EScSG activity index is good, though the lung-related disease activity may not be sufficiently represented. Further validation steps may be required for both the EScSG and our 12-point activity index.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20236952     DOI: 10.1093/rheumatology/keq022

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  6 in total

Review 1.  Assessment of skin involvement in systemic sclerosis.

Authors:  Gábor Kumánovics; Márta Péntek; Sangmee Bae; Daniela Opris; Dinesh Khanna; Daniel E Furst; László Czirják
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

2.  Assessment of fatigue and its relationships with disease-related parameters in patients with systemic sclerosis.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Rachida Bensabbah; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2011-12-21       Impact factor: 2.980

Review 3.  Patient-reported outcome instruments in clinical trials of systemic sclerosis.

Authors:  John D Pauling; Joana Caetano; Corrado Campochiaro; Giacomo De Luca; Ana Maria Gheorghiu; Maria Grazia Lazzaroni; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2019-11-25

4.  The challenges and controversies of measuring disease activity in systemic sclerosis.

Authors:  Laura Ross; Murray Baron; Mandana Nikpour
Journal:  J Scleroderma Relat Disord       Date:  2018-03-27

5.  Lung ultrasound in systemic sclerosis: correlation with high-resolution computed tomography, pulmonary function tests and clinical variables of disease.

Authors:  Antonietta Gigante; Filippo Rossi Fanelli; Silvio Lucci; Giuseppe Barilaro; Silvia Quarta; Biagio Barbano; Antonello Giovannetti; Antonio Amoroso; Edoardo Rosato
Journal:  Intern Emerg Med       Date:  2015-10-22       Impact factor: 3.397

6.  Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis.

Authors:  Katja Lakota; Mary Carns; Sofia Podlusky; Katjusa Mrak-Poljsak; Monique Hinchcliff; Jungwha Lee; Matija Tomsic; Snezna Sodin-Semrl; John Varga
Journal:  PLoS One       Date:  2015-01-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.